Clinical Trial Update: Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a bortezomib, thalidomide, and dexamethasone regimen after autologous stem cell transplant in stage I-III multiple myeloma; results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Thalidomide (thalidomide)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Multiple Myeloma and Plasma Cell Neoplasm, Neurotoxicity | Phase 2 | Status: COMPLETED | Results posted: 2020-09-17